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Background: The DEK protein is related to chromatin reconstruction and gene transcription, and plays an
important role in cell apoptosis. High expression levels of the human DEK gene have been correlated with
numerous human malignancies. This study explores the roles of DEK in tumor progression and as a prognostic
determinant of colorectal cancer.
Methods: Colorectal cancer specimens from 109 patients with strict follow-up, and colorectal adenomas from 52
patients were selected for analysis of DEK protein by immunohistochemistry. The correlations between DEK over
expression and the clinicopathological features of colorectal cancers were evaluated by Chi-square test and Fisher’s
exact tests. The survival rates were calculated by the Kaplan-Meier method, and the relationship between
prognostic factors and patient survival was also analyzed by the Cox proportional hazard models.
Results: DEK protein showed a nuclear immunohistochemical staining pattern in colorectal cancers. The strongly
positive rate of DEK protein was 48.62% (53/109) in colorectal cancers, which was significantly higher than that in
either adjacent normal colon mucosa (9.17%, 10/109) or colorectal adenomas (13.46%, 7/52). DEK over expression in
colorectal cancers was positively correlated with tumor size, grade, lymph node metastasis, serosal invasion, late
stage, and disease-free survival- and 5-year survival rates. Further analysis showed that patients with late stage
colorectal cancer and high DEK expression had worse survival rates than those with low DEK expression. Moreover,
multivariate analysis showed high DEK expression, serosal invasion, and late stage are significant independent risk
factors for mortality in colorectal cancer.
Conclusions: DEK plays an important role in the progression of colorectal cancers and it is an independent poor
prognostic factor of colorectal cancers.
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The DEK gene, on chromosome 6, encodes a 375-amino
acid protein with an estimated molecular weight of 43kD.
It has not been classified into any known protein family
[1-3]. Human DEK is an abundant nuclear protein with
important functions in the architectural regulation of chro-
matin assembly. It was originally identified as a fusion with
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reproduction in any medium, provided the orleukemia (AML) patients, and was named on the basis of
the initials of the patient DK [4,5].
Since its discovery as the target of the t(6;9) translocation
in a subset of AML patients, DEK has been repeatedly as-
sociated with tumor development. High expression levels
of the human DEK gene have been correlated with numer-
ous human malignancies such as glioblastoma, melanoma,
breast cancer, ovarian cancer and hepatocellular carcinoma
[1,4,6,7]. To date, no mutations have been reported in the
coding sequence of human DEK. However, various other
regulatory mechanisms have been identified at the DNA,
RNA, and protein levels [6-8]. Intracellularly, DEK has been
described to induce DNA supercoiling, DNA replication,
RNA splicing and transcription in vitro [4,8,9]. Wise-
Draper et al. demonstrated that DEK suppresses cellular. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epithelial transformation in vitro and in vivo [10]. Datta
et al. recently reported that oncoprotein DEK is up-
regulated in bladder cancer tissues in comparison with nor-
mal counterparts as determined by western blot. Indeed,
DEK protein was shown to be present in the voided urine
of patients with both low- and high-grade bladder cancer,
suggesting that DEK could be used as a biomarker for de-
tection of this cancer using patient urine samples [11]. Our
previous study [12] showed that DEK protein expression
was closely related with the proliferation of both ovarian
and breast cancers, and that its over expression was signifi-
cantly correlated with the increased Ki-67 proliferation
index in uterine cervical cancers. These studies suggest that
DEK activities may be essential for cancer progression.
Therefore, DEK depletion has been suggested as a novel
therapeutic method for cancer-targeted therapy.
However, to date, the expression status of DEK in
colorectal cancer and its relationship with clinicopatho-
logical features/prognosis is unknown [13-15]. To deter-
mine whether DEK is important in the tumorigenesis of
colorectal cancers and investigate its prognostic value,
109 cases of colorectal cancer and 52 colorectal
adenoma tissues were selected for the analysis of DEK
by immunohistochemical staining. Additionally, the prog-
nostic significance of carcinoembryonic antigen (CEA), a
well-established prognostic factor for colorectal cancer,
was also analyzed to verify the reliability of this cohort of
colorectal cancer patients. Our data uncovered that DEK
is frequently upregulated in colorectal cancers when
compared with either the normal tissues counterparts or
colorectal adenomas. These findings suggest that DEK
may be an independent predictor for poor prognosis in
patients with colorectal cancer.
Methods
Ethics statement
This study complied with the Helsinki Declaration and
was approved by the Human Ethics the Research Ethics
committees of the Dandong Center Hospital of China.
Through the surgery consent form, patients were in-
formed that the resected specimens were kept by our
hospital and might be used for scientific research, and
that their privacy would be maintained. Follow-up
survival data were collected retrospectively through
medical-record analyses.
Tissue specimens and follow-up observation
The routinely processed and diagnosed colorectal cancer
tissues (109 cases) with strict follow-up were randomly
selected from the patients who underwent surgery be-
tween 2004 and 2007 in the Dandong Center Hospital of
China. Pathological parameters, including age, gender,
grade, nodal metastasis, clinical stage and survival data,were carefully reviewed in all cases. The patients’ ages
ranged from 34 to 76 years with a mean age of 48.6 yrs.
The male to female ratio was 87:22. The tumor location
was categorized as colonic and ileocecal in 57 cases, and
rectal in 52 cases. The hematoxylin and eosin-stained
slides of the different biopsies were reviewed by two
experienced pathologists and one appropriate paraffin
block was selected for this study. Staging was performed
according to the TNM and FIGO classification of carcin-
oma of the colon and rectum. From these 109 tumor
tissues, 59 were FIGO stage I-IIA, which is considered
early stage. Fifty samples were stage IIB-IIIC, an ad-
vanced stage according to the Union for International
Cancer Control 7th Edition criteria and the World
Health Organization classification (Pathology & Genetics
Tumors of the digestive system) [16]. Of the 109 cases,
49 were well-differentiated and 60 were poorly differen-
tiated cancers. Adjacent normal colon mucosa tissues
from the cancer resection margin and 52 colorectal ad-
enoma tissues were also included in this study. Before
surgery, no patients had received chemotherapy or had
distant metastases, and all patients had serum CEA de-
tection (0-5 μg/ml as normal). The 109 cancer patients
were followed-up for survival. By March 2012, 39 pa-
tients had died while 70 patients remained alive. The
median survival time was 56 months.
Immunohistochemistry for DEK in paraffin-embedded
tissues
Immunohistochemical analysis was performed using the
DAKO LSAB kit (DAKO A/S, Glostrup, Denmark).
Briefly, to eliminate endogenous peroxidase activity, 4 μm
thick tissue sections were deparaffinized, rehydrated and
incubated with 3% H2O2 in methanol for 15 min at room
temperature (RT). The antigen was retrieved at 95°C for
20 min by placing the slides in 0.01 M sodium citrate
buffer (pH 6.0). The slides were then incubated with
DEK antibody (1:50, BD Biosciences Pharmingen, CA,
USA) at 4°C overnight. After incubation with biotinylated
secondary antibody at RT for 30 min, the slides were incu-
bated with streptavidin-peroxidase complex at RT for
30 min. Immunostaining was developed by using 3,3′-
diaminobenzidine, and Mayer’s hematoxylin was used
for counterstaining. We used tonsil sections as the posi-
tive controls and Mouse IgG as an isotope controls. In
addition, the positive tissue sections were processed with
omitting of the primary antibody (mouse anti-DEK) as
negative controls.
Evaluation of immunohistochemical staining
All specimens were examined by two pathologists (Lin Z
& Liu S) who did not possess knowledge of the clinical
data. In case of discrepancies, a final score was established
by reassessment on a double-headed microscope. Briefly,
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scored as ‘-’ (negative, no or less than 5% positive cells), ‘+’
(5–25% positive cells), ‘++’ (26–50% positive cells) and
‘+++’ (more than 50% positive cells). Only the nuclear
expression pattern was considered as positive staining.
The strongly positive descriptor (DEK over expression)
was assigned to ‘++’ and ‘+++’ scored cells. For survival
analysis, DEK expression level was denoted as high ex-
pression (‘++’ and ‘+++’) and low expression (‘-’ and ‘+’).
Statistical analysis
Statistical analyses were performed using the SPSS 17.0.
Correlation between DEK expression and clinicopatholog-
ical characteristics were evaluated by Chi-square test and
Fisher’s exact tests. The survival rates after tumor removal
were calculated by the Kaplan-Meier method, and differ-
ences in survival curves were analyzed by the Log-rank
tests. Multivariate survival analysis was performed on all
the significant characteristics measured by univariate
survival analysis (gender, age, tumor size, differenciation,
lymph node metastasis, serosal invasion, tumor stage,
CEA level, and DEK expression) through the Cox propor-
tional hazard regression model. P<0.05 was considered
statistically significant.Figure 1 Immunohistochemical staining of DEK protein in colorectal c
negative for DEK protein in normal colorectal mucosa (Original magnificati
adenomas (Original magnification, ×200). (C) DEK is negative in colorectal
(D) DEK is strongly positive in the cancer cells of colorectal cancer with lym
in the signet ring cells of colorectal cancers. (F) DEK is strongly positive in
magnification, ×100).The variables such as CEA level, DEK expression, stages,
and differentiations were grouped two as normal vs in-
creased level of CEA, high expression vs low expression of
DEK, early stage (I-IIA) vs late stage (IIB-IIIC), and well vs
poorly and moderately differentiated, respectively.
Results
DEK protein is over expressed in colorectal cancer
DEK protein expression showed a nuclear immunohisto-
chemical staining pattern in colorectal cancers (Figure 1).
The positive rate of DEK protein expression was signifi-
cantly higher in colorectal cancer tissues (95.41%, 104/
109) than in either normal adjacent mucosa (33.03%, 36/
109) or colorectal adenomas (32.69%, 17/52). Similarly,
the strongly positive rate of DEK protein was 48.62%
(53/109) in colorectal cancers, which was significantly
higher than that in either adjacent normal colon mucosa
(9.17%, 10/109) or colorectal adenomas (13.46%, 7/52)
(P<0.01, respectively) (Table 1).
Clinicopathological and prognostic significance of DEK
over expression
To evaluate the relationship between DEK protein and
colorectal cancer progression, we analyzed the correlationancer, adenoma, and normal mucosa. (A) DEK is absolutely
on, ×100). (B) DEK is positive in the dysplastic cells of colorectal
cancer without lymph node metastasis (Original magnification, ×200).
ph node metastasis (Original magnification, ×200). (E) DEK is positive
the metastatic cancer cells (arrows) in lymph node (Original









- + ++ +++
Normal 109 73 26 10 0 33.03% 9.17%
Adenoma 52 35 10 7 0 32.69% 13.46%
Cancer 109 5 51 23 30 95.41%** 48.62%**
**P<0.01, compared with peripheral normal mucosa and adenomas of colon.
Adenoma: colorectal adenoma; Cancer: colorectal cancer;
Positive rate: percentage of positive cases with ‘+’, ‘++’, and ‘+++’
staining score;
Strongly positive rate: percentage of positive cases with ‘++’ and ‘+++’
staining score.
Table 2 Chi-square test and Fisher’s exact test of
relationship between DEK over expression and the










Male 87 45 (51.72%)
Female 22 8 (36.36%)
Age (years old) 1.298
(0.611-2.756)
0.497
≥49 53 24 (45.28%)
<49 56 29 (51.79%)
Tumor size (cm) 2.353
(1.086-5.101)
0.029
≤5 61 24 (39.34%)




Colonic & ileocecal 57 27 (47.37%)




Well diff. 49 17 (34.69%)






- 60 22 (36.67%)




- 57 17 (29.82%)




I-IIA 59 22 (37.29%)




Normal 37 15 (40.54%)
Increased 72 38 (52.78%)
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logical features of colorectal cancers. The strongly positive
rate of DEK protein was significantly higher in colorectal
cancers with >5 cm tumor size than in cases with ≤5 cm
tumor size (P=0.029). Similarly, we found that the strongly
positive rate of DEK protein was significantly higher in
colorectal cancers with lymph node metastasis (63.27%,
31/49) than in cases without metastasis (36.67%, 22/60)
(P=0.006). It was also higher in poorly and moderately
differentiated colorectal cancers (60.00%, 36/60) than in
well-differentiated cases (34.69%, 17/49) (P=0.009). For
the TNM and FIGO clinical stages, the strongly positive
rate of DEK protein was 62.00% (31/50) in the advanced
stage (IIB–IIIC) colorectal cancers, but only 37.29% (22/
59) in early stage cases (I–IIA) (P=0.010). Meanwhile, the
strongly positive rate of DEK protein was higher in cancer
cases with serosal invasion (50.00%, 26/52) than in those
with no serosal invasion (P=0.031). However, the over ex-
pression of DEK protein was not related with gender, age,
tumor location or CEA levels of patients with colorectal
cancer (Table 2). Moreover, patients with colorectal cancer
with high DEK expression had lower disease-free and 5-
year survival rates than those without high DEK expres-
sion as determined using the Kaplan-Meier method
(P<0.0001) (Figure 2A-B).
To further substantiate the importance of high DEK
expression in colorectal cancer progression, we com-
pared its effect on prognosis by analyzing the correla-
tions between DEK expression and factors associated
with aggressiveness of colorectal cancer. Serosal inva-
sion, lymph node metastasis, CEA level and tumor stage
were all associated with lower 5-year survival rates
(P<0.001). By combination analysis, (Figure 3A), we
found that colorectal cancer with serosal invasion con-
comitant with DEK expression had a significantly lower
5-year survival rate than that without DEK expression
(P<0.0001). Similarly, colorectal cancer with lymph node
metastasis and high DEK expression, had a significantly
lower 5-year survival rate than colorectal cancer with
lymph node metastasis in the absence of DEK expression(Figure 3B, P=0.001). In addition, colorectal cancer pa-
tients with high CEA levels concomitant with high DEK
expression had lower 5-year survival rates than those
without DEK expression (Figure 3C, P<0.0001). Most
importantly, late-stage colorectal cancers concomitant
with high DEK expression had the lowest 5-year survival
rate, which was significantly lower than those without
high DEK expression (Figure 3D, P=0.004).
Figure 2 Kaplan-Meier analyses of disease-free and 5-year survival rates in 109 colorectal cancer patients in relation to DEK protein
over expression. Patients with colorectal cancer with high DEK expression had lower disease-free (A, P<0.0001) and 5-year (B, P<0.0001) survival
rates than those with without high DEK expression as determined using the Kaplan-Meier method. (H, high; L, low).
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in colorectal cancers by Cox proportional hazard
regression model
Using univariate analysis, we found that colorectal can-
cer patients with DEK over expression had significantly
lower 5-year survival rates than those without DEK-
overexpressing tumors. Additionally, serosal invasion,
tumor stage, and CEA level were also associated with 5-
year survival rates when DEK was expressed (Table 3).
These data suggest that DEK could also be a valuable
prognostic factor in colorectal cancer. Therefore, multi-
variate analysis was performed using the Cox propor-
tional hazards model for all of the significant variables
examined in the univariate analysis. We found that se-
rosal invasion (HR: 1.708, 95% CI: 1.414–2.555, P=0.009)
and late stage (HR: 1.663, 95% CI: 1.081–2.558, P=0.021)
proved to be independent prognostic factors for survival
in colorectal cancer (Table 4). This result validates the
clinical application that elevated CEA level and serosal in-
vasion predict poor survival of patients with colorectal
cancer. Importantly, DEK over expression emerged as a
significant independent prognostic factor in colorectal can-
cer (HR: 1.805, 95% CI: 1.208–2.699, P=0.004) (Table 4).
Discussion
Colorectal cancer is the most common malignancy of the
gastrointestinal tract [17]. It causes 655,000 deaths world-
wide every year [18]. As a high-risk and highly metastatic
cancer, the identification of reliable criteria for predicting
recurrence and for identifying colorectal tumors is of great
interest not only for understanding the molecular and cel-
lular processes involved, but also for uncovering possible
new therapeutic molecular targets.DEK was discovered by the identification of transloca-
tion t(6;9) (p23;q34) in a subset of patients with AML.
In fact, this translocation has been considered for use in
AML patient stratification. Chromosomal alterations at
the DEK locus are now known not to be a universal fea-
ture of malignancy, even in AML. However, the increasing
list of tumor types, including AML [19,20], glioblastoma
[21], hepatocellular carcinoma [22], melanoma [23], ovar-
ian cancer [12], cervical cancer [24] and others [25-27],
showing high DEK protein expression raises the exciting
possibility of using DEK as a tumor marker [6]. Kappes
et al. investigated the localization of DEK throughout the
cell cycle and found it was always on chromatin and as a
component of mitotic chromosomes [28]. Khodadoust
et al. reported that DEK expression levels can distinguish
benign nevi from malignant melanomas, indicating that
this protein may prove to be highly useful for differentia-
ting diagnosis [29]. This is a prime example of a clinically
relevant setting in which this protein may prove to be
highly useful. Trisha et al. used littermate DEK knockout,
heterozygous and wild type mice for their experiments,
and found that there was a significant delay in the forma-
tion of papillomas in DEK knockout mice compared with
wild type and heterozygous mice. Our previous data also
showed that DEK protein was strongly positive in breast
cancers and DCIS (ductal carcinoma in situ), but negative
in normal breast glands, demonstrating that DEK protein
expression levels might be used as a biomarker for early
diagnosis of breast cancers [30].
Babaei-Jadidi R et al. reported that accumulation of
DEK and loss of epithelial TPM may contribute to the
oncogenicity of FBXW7 mutation in both human colorec-
tal cancer and in the ApcMin/+/Fbxw7ΔG mouse intestine,
Figure 3 Kaplan-Meier analysis of 5-year survival rates in 109 patients with or without DEK highly expressed colorectal cancer in
relation to serosal invasion (SI), lymph node (LN) metastasis, CEA level, and tumor stage. (A) Colorectal cancer with serosal invasion
concomitant with DEK expression had a significantly lower 5-year survival rate than that without DEK expression (P<0.0001). (B) Colorectal cancer
with lymph node metastasis and high DEK expression, had a significantly lower 5-year survival rate than colorectal cancer with lymph node
metastasis in the absence of DEK expression (P=0.001). (C) Colorectal cancer patients with high CEA levels concomitant with high DEK expression
had lower 5-year survival rates than those without DEK expression (P<0.0001). (D) Late-stage colorectal cancers concomitant with high DEK
expression had the lowest 5-year survival rate, which was significantly lower than those without high DEK expression (P=0.004). (H, high; L, low).
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colorectal tumorigenesis. And DEK expressions in epithe-
lial cells are correlated with FBXW7 mutations in human
colorectal cancer [31]. However, DEK protooncogene
function and the regulation of its expression levels are
largely unclear. The overall goal of this study was to deter-
mine whether the over expression of DEK oncoprotein
might serve as a biomarker for the prognostic evalu-
ation of colorectal cancers. This is the first study, to ourknowledge, to correlate DEK levels in colorectal cancers
with histological prognostic factors to understand the
role of DEK up regulation in colorectal cancer progres-
sion. Here we performed immunohistochemical staining
of DEK protein and survival data analysis using 52 of
colon adenomas and 109 of colorectal adenocarcinomas
and their adjacent normal tissue counterparts. We
found that the positive and strongly positive rates of
DEK oncoprotein were significantly higher in colorectal
Table 3 Univariate survival analyses (Cox regression model) of various factors in patients with colorectal cancer
Factors B SE Wald HR 95% CI P value
Lower Upper
Gender 0.235 0.239 0.971 1.266 0.445 0.946 0.324
Age 0.266 0.192 1.908 1.304 0.895 1.901 0.167
Tumor size 0.059 0.193 0.093 1.061 0.727 1.548 0.760
Location 0.024 0.192 0.016 1.025 0.704 1.492 0.899
Differentiation 0.265 0.193 0.736 1.180 0.809 1.722 0.391
Lymph node metastasis 0.374 0.193 3.756 1.454 0.996 2.123 0.053
Serosal invasion 0.437 0.192 5.155 1.547 1.062 2.256 0.023*
Tumor stage 0.741 0.194 14.573 2.098 1.434 3.069 <0.0001*
CEA 0.475 0.203 5.468 1.607 1.080 2.392 0.019*
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adenomas. These findings indicate that DEK potentially
plays important roles in the progression of colorectal
cancer (Table 1).
Moreover, as DEK may be present at higher levels in
immature cells than in differentiated counterparts, it could
also aid in gauging the differentiation potential of tumor
cells. Kavanaugh et al. reported that DEK over expression
promotes the transformation of human keratinocytes, and
that DEK knockout mice are partially resistant to chem-
ically induced papilloma formation [32]. Shibata et al. also
showed that DEK over expression, partly through an in-
crease in its gene dose, mediates the activity of global
transcriptional regulators and is associated with tumor ini-
tiation activity and poor prognosis in high-grade neuroen-
docrine carcinoma [33]. Here we demonstrate that DEK
over expression correlated with large tumor size, low
differentiation, serosal invasion, lymph node metastasis,
and late-stage in colorectal carcinomas. However, DEKTable 4 Multivariant survival analyses (Cox regression
model) of various factors in patients with colorectal
cancer
Factors B SE Wald HR 95% CI P
valueLower Upper
Serosal invasion 0.535 0.206 6.778 1.708 1.141 2.555 0.009*
Tumor stage 0.509 0.220 5.366 1.663 1.081 2.558 0.021*
CEA 0.347 0.228 2.305 1.415 0.904 2.214 0.129






*Significant different.expression level was not correlated with gender, age,
tumor location or CEA level in patients with colorectal
cancers (Table 2). These results indicate that DEK might
be a new attractive molecular target for therapy.
Despite the strong association between DEK expres-
sion and cancer, reports of DEK expression-based out-
come in tumor patients are limited. Using SAGE (Serial
Analysis of Gene Expression) and real-time polymerase
chain reaction (PCR), Abba et al. found that DEK and
DCTN3 are significantly over expressed in breast carcin-
omas with lymph node metastasis or poor prognosis
[34]. Privette Vinnedge et al. demonstrated that DEK
expression is associated with positive hormone receptor
status in primary breast cancers and is up-regulated
in vitro following exposure to the hormones estrogen,
progesterone, and androgen. Moreover, chromatin im-
munoprecipitation experiments identified DEK as a
novel estrogen receptor-α target gene whose expression
promotes estrogen-induced proliferation. These data
suggest that DEK promotes the pathogenesis of ER+
breast cancer and that the targeted inhibition of DEK
may enhance the efficacy of conventional hormone ther-
apies [2]. Similarly, our previous study reported that the
strongly positive rate of DEK protein was significantly
higher in breast cancers with <3 years disease-free sur-
vival than in cases with ≥3 years disease-free survival,
suggesting that the detection of >25% DEK expression
levels could play a role as a marker of poor prognosis in
breast cancer [30]. Here we have demonstrated that
high DEK expression is associated with serosal invasion,
lymph node metastasis, tumor size and differentiation,
which are crucial histological features associated with
poor prognosis in colorectal cancer. We demonstrated
that colorectal cancers exhibiting serosal invasion, lymph
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vival rates. Importantly, DEK over expression concomitant
with any of these features correlated with significantly
lower 5-year survival rates than those without DEK ex-
pression. Of particular interest, high DEK expression was
found to be an independent hazard factor in colorectal
cancer. These findings raise the possibility that DEK not
only facilitates serosal invasion, lymph node metastasis,
and CEA elevation but also aggressive cancer behavior,
resulting in poor prognosis for patients. Importantly, we
demonstrated that colorectal cancer with high DEK ex-
pression correlated with late-stage tumors. Tumor stage is
an independent prognostic factor in other studies and as
well as in our study [16,35] (Figure 3 and Tables 3 and 4).
Conclusion
In conclusion, we have identified DEK as a potential
biomarker for evaluation of tumor progression and prog-
nosis of colorectal cancers. DEK expression was more
commonly seen in cases presenting with poor prognostic
factors of colorectal cancer, leading to lymph node me-
tastasis, late-stage, serosal invasion and reduced survival
time. Further studies are warranted to more firmly es-
tablish this supposition.
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